➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
Medtronic
Harvard Business School
Mallinckrodt
AstraZeneca

Last Updated: October 24, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DIGOXIN PEDIATRIC

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Digoxin Pediatric

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000476 Digitalis Investigation Group (DIG) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1990-06-01 To determine if digitalis had a beneficial, harmful, or no effect on total mortality in patients with clinical heart failure and sinus rhythm.
NCT00000547 Enalapril After Anthracycline Cardiotoxicity Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1994-04-01 To determine if the chronic administration of enalapril, an inhibitor of angiotensin converting enzyme (ACE), reduces progression of cardiac dysfunction in pediatric oncology patients who have received anthracyclines, and who are not currently on digoxin, diuretics, or vasodilators for heart failure.
NCT00000556 Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1995-03-01 To compare two standard treatment strategies for atrial fibrillation: ventricular rate control and anticoagulation vs. rhythm control and anticoagulation.
NCT00006330 Pharmacokinetic and Pharmacodynamic Interaction Study of Digoxin and Hawthorn Completed National Center for Research Resources (NCRR) N/A 1969-12-31 Hawthorn (Crataegus oxyacantha) is a natural product that is popular in European and American herbal medicine practice. Some of its cardiac uses include the treatment of high and low blood pressure, rapid heart beat, chest pain, and blocked arteries. In many cases, it is used as an adjuvant agent with other cardiac drugs such as digoxin, amiodarone, and warfarin. To date, little information is known about the effect of hawthorn when taken with other drugs and if toxicities occur when hawthorn is used with other drugs. The purpose of this study is to examine the interaction between digoxin and hawthorn in eight healthy subjects. Subjects will be recruited by advertisement. The design of the study will include a 10-day and a three-week treatment phase of digoxin 0.125 mg - 0.25 mg/day and hawthorn (Crataegus special extract WS1442, Schwabe Co.) 450 mg twice daily or placebo, with a randomized crossover. There will be a three-week washout period in between treatment phases. On day 10 (phase I) and day 21 (phase II), subjects will have 12 blood samples drawn for pharmacokinetic analysis. The plasma samples will be measured for digoxin concentration. Additionally, the subjects will be assessed for any clinical toxicities or adverse events. The significance of this study is to provide the clinician with information regarding the safe use of digoxin in combination with the herbal supplement, hawthorn.
NCT00007605 Comparing the Effects of Amiodarone, Sotalol, and Placebo in Maintaining Sinus Rhythm in Patients With Atrial Fibrillation Converted to Sinus Rhythm Completed VA Office of Research and Development Phase 3 1998-04-01 Atrial fibrillation is the most frequently occurring cardiac arrhythmia, with 1.0-1.5 million cases annually. It is a risk factor for congestive heart failure, and stroke, 75,000 cases of the latter occurring annually in patients with atrial fibrillation. The safety of the most widely used antiarrhythmic agent for this group of patients, quinidine, has been called into question. This study seeks to determine whether two other agents, amiodarone and sotalol, are safe and effective treatments for patients with atrial fibrillation.
NCT00027014 Herb-Opioid Interactions Completed National Center for Complementary and Integrative Health (NCCIH) Phase 4 2001-09-01 This is a series of studies in healthy volunteers to assess the potential for adverse interactions between St. John's wort (SJW) extract and two narcotic (opioid) pain medications: oxycodone and fentanyl. In the case of oxycodone, we are interested in whether SJW treatment promotes the metabolism of oxycodone, such that it lowers the effectiveness of standard doses of oxycodone in treating pain problems. For the fentanyl study, we will investigate whether SJW treatment will interfere with the delivery of fentanyl to the brain and diminish it's effectiveness to relieve pain. There is evidence to suggest that SJW treatment may increase the activity of a transporter protein, named P-glycoprotein (Pgp), in the blood-brain barrier (BBB) that protects the brain from exposure to drugs and other dietary and environmental toxins.
NCT00064857 Pycnogenol for the Treatment of Lymphedema of the Arm in Breast Cancer Survivors Completed National Center for Complementary and Integrative Health (NCCIH) Phase 2 2003-08-01 The goal of this study is to evaluate the effectiveness of a standardized botanical extract of Pycnogenol as a treatment for stable arm lymphedema in breast cancer survivors.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Digoxin Pediatric

Condition Name

Condition Name for Digoxin Pediatric
Intervention Trials
Healthy 29
Heart Failure 11
Atrial Fibrillation 11
Healthy Volunteers 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Digoxin Pediatric
Intervention Trials
Heart Failure 20
Atrial Fibrillation 17
Heart Diseases 5
Breast Neoplasms 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Digoxin Pediatric

Trials by Country

Trials by Country for Digoxin Pediatric
Location Trials
United States 136
Germany 18
Canada 15
United Kingdom 10
France 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Digoxin Pediatric
Location Trials
Texas 19
Florida 9
California 9
Ohio 8
New York 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Digoxin Pediatric

Clinical Trial Phase

Clinical Trial Phase for Digoxin Pediatric
Clinical Trial Phase Trials
Phase 4 23
Phase 3 15
Phase 2/Phase 3 3
[disabled in preview] 121
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Digoxin Pediatric
Clinical Trial Phase Trials
Completed 98
Not yet recruiting 27
Recruiting 24
[disabled in preview] 26
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Digoxin Pediatric

Sponsor Name

Sponsor Name for Digoxin Pediatric
Sponsor Trials
Boehringer Ingelheim 12
Bristol-Myers Squibb 8
AstraZeneca 6
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Digoxin Pediatric
Sponsor Trials
Other 132
Industry 101
NIH 12
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Mallinckrodt
McKinsey
Express Scripts
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.